Skip to main content
. 2022 Oct 7;30:311–322. doi: 10.1016/j.omtn.2022.10.001

Figure 6.

Figure 6

MIR145 promoter methylation analysis results in superior clinical benefit of multivariate prognostic models

(A and B) Kaplan-Meier survival curves for the PFS of NMIBC (A) and the OS of MIBC (B) patients according to multivariate models of MIR145 core promoter methylation with EORTC-risk group and tumor stage, respectively. p-values calculated by log-rank test. (C and D) Decision curve analysis of the “control” and the “MIR145 methylation-fitted” multivariate prognostic models for the PFS of NMIBC (C) and OS of MIBC (D) patients.